Calidi Biotherapeutics, Inc.

CLDI NYSE SEC CIK 1855485
Follow Calidi Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.6M +29.2% vs same quarter last year
EPS, diluted −$1.47
Operating cash flow −$2.3M +44.8% vs same quarter last year
Operating income −$4.3M +13.9% vs same quarter last year
Net income by quarter
−$4.1M
−$5M
−$5.7M
−$5.1M
−$4.1M
−$4.1M
−$4.2M
−$3.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$30M−$20M−$10M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$19.9M
FY24−$22.1M
FY23−$29.2M
FY22-
FY21-